In our laboratory, we are working on four research projects including the clinical research project to optimize the drug prescription for each patient based on the information of therapeutic drug monitoring (TDM) and pharmacogenomics (PGx), and the research project to detect the law-evading drugs and their metabolites.
- The research to optimize the drug prescription for each patient by using pharmacokinetics (PK)/PGx analysis; In collaboration with Gifu University Hospital and other clinical facilities, we try to find out the best way to optimize the drug prescription for each patient. The combined analysis of PK using TDM by HPLC and LC-MS/MS as well as PGx to detect the genetic polymorphisms with clinical outcome during drug therapy (ex. the effectiveness and adverse events) would be utilized.
- The research related to the law-evading drugs (also known as legal highs); in collaboration with several research facilities and local government, we try to establish the systems to monitor and identify the law-evading drugs and their metabolites, in order to prevent their illegal use. We also plan to find out the mechanisms of actions of these drugs.
- Overcoming the adverse events induced by anticancer drugs; the adverse events induced by anticancer drugs deteriorate quality of life (QOL), subsequently discontinuing the cancer treatment or decreasing their dosage. In this study, especially focusing on the skin toxicity induced by frequently-used anti-EGFRs, we aim to find new molecule(s) to ameliorate skin toxicity.
- The research related to aquaporin; the aim of this study is to elucidate the mechanisms of trafficking of aquaporin to regulate the transport of water, and to explore the possibility of regulators as drug targets.
- To establish the systems of therapeutic drug monitoring and its application in clinical in order for clinical pharmacists to be positively involved in pharmacological therapy
- To prevent the illegal use of law-evading drugs (also known as legal highs)
- To ameliorate the adverse events induced by anticancer drugs
- To elucidate the mechanism of trafficking of aquaporin
- Nawata et al., Prevention of drug priming- and cue-induced reinstatement of MDMA-seeking behaviors by the CB1 cannabinoid receptor antagonist AM251, Drug Alcohol Depend., in press.
- Hayashi et al., Simultaneous and rapid determination of gefitinib, erlotinib, and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer, Biomed Chromatogr., in press.
- Miura et al., Anti-androgenic activity of icarisid II from epimedium herb in prostate cancer LNCaP Cells, J Nutr Sci Vitaminol (Tokyo)., 61, 201-204 (2015).
- Soda et al., Simple HPLC method for the determination of caspofungin in human plasma, Clin Pharmacol Biopharm., 4, 138 (2015).
- Hayashi et al., Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation, Anticancer Res., 34, 7271-7277 (2014).
- Iguchi et al., Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells, Oncol Lett., 7, 1665-1668 (2014).
- Matsunaga et al., Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10, Toxicol Appl. Pharmacol., 278, 180-189 (2014).